BioNexus Gene Lab Corp BGLC
BioNexus Gene Lab Corp. is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. ("Chemrex") and MRNA Scientific Sdn. Bhd. ("MRNA Scientific"). Chemrex is engaged in the distribution of chemical raw materials, primarily for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management.
In November 2025, the Company entered into a Share Subscription and Shareholders' Agreement with Fidelion Diagnostics Pte. Ltd. ("Fidelion") and related parties, and also entered into an exclusive Southeast Asia intellectual property license arrangement relating to the VitaGuard™ minimal residual disease platform. These transactions expanded the Company's strategic focus in molecular diagnostics and oncology-related screening technologies.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.4M | $9.5M | $9.8M | $10.9M | $13.4M | $11.4M | $127.0K | $212.3K | — |
| Cost of revenue | $6.3M | $8.2M | $8.4M | $9.7M | $11.1M | $9.7M | $71.1K | -$183.6K | — |
| Gross profit | $1.1M | $1.3M | $1.3M | $1.3M | $2.3M | $1.7M | $55.9K | $28.8K | — |
| R&D | $50.7K | $47.5K | $55.0K | — | — | — | — | — | — |
| SG&A | $1.5M | $1.8M | $2.4M | $1.7M | $1.3M | $1.3M | $356.6K | -$241.9K | — |
| Total operating expenses | $4.5M | $4.9M | -$4.4M | — | — | — | — | — | — |
| Operating income | -$3.0M | -$1.6M | -$2.6M | -$291.2K | $1.1M | $1.3M | -$275.7K | $59.9K | — |
| Interest expense | — | — | $13.9K | $12.5K | — | — | — | — | — |
| Pre-tax income | -$3.0M | -$1.6M | -$2.6M | -$303.7K | $1.0M | — | -$221.7K | $59.9K | — |
| Income tax | $0 | $3.5K | $21.5K | $52.3K | $291.3K | — | $24.8K | $33.4K | — |
| Net income | -$3.0M | -$1.6M | -$2.6M | -$356.0K | $751.6K | $1.1M | -$246.5K | $26.5K | — |
| EPS, diluted | — | -0.09 | -0.17 | — | — | 0.01 | 0.00 | 0.00 | — |
| Shares, diluted (wtd. avg.) | — | $17.8M | $15.9M | — | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.5M | $2.9M | $4.5M | $2.1M | $2.1M | $2.8M | $859.1K | $1.3M | — |
| Receivables | $505.9K | $1.4M | — | — | — | — | — | — | — |
| Inventory | $676.7K | $1.4M | $1.1M | $977.8K | $1.5M | $1.2M | $7.6K | $15.3K | — |
| Total current assets | $5.4M | $7.4M | $8.0M | $6.0M | $7.1M | $8.0M | $882.6K | $1.3M | — |
| Property, plant and equipment | $1.6M | $1.5M | $1.5M | $1.5M | $1.6M | $1.8M | $312.9K | $341.8K | — |
| Total assets | $9.3M | $10.4M | $11.4M | $8.7M | $9.6M | $10.1M | $1.2M | $1.7M | — |
| Accounts payable | — | $1.5M | $1.4M | $1.9M | $2.0M | — | — | — | — |
| Total current liabilities | $521.0K | $2.0M | $1.6M | $2.0M | $2.3M | $3.4M | $51.6K | $62.9K | — |
| Total liabilities | $637.9K | $2.1M | $1.7M | $2.1M | $2.4M | $3.5M | $108.9K | $130.3K | — |
| Retained earnings | -$6.4M | -$3.4M | -$1.8M | $1.2M | $1.5M | $760.8K | -$333.3K | -$86.8K | — |
| Total equity | $8.6M | $8.3M | $9.7M | $6.7M | $7.2M | $6.7M | $1.1M | $1.5M | $94.6K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.8M | -$2.1M | -$1.8M | $551.8K | $9.2K | $552.7K | -$217.3K | -$274.1K | — |
| Depreciation and amortisation | $111.9K | $104.2K | $83.3K | $91.4K | $91.3K | $90.8K | $41.7K | $40.6K | — |
| Stock-based compensation | $794.8K | $141.0K | — | — | — | — | — | — | — |
| Capital expenditure | $37.0K | $227.0K | $149.4K | $0 | $3.2K | $421.6K | $12.8K | $39.6K | — |
| Investing cash flow | $944.8K | $418.2K | -$1.8M | -$450.5K | -$490.6K | $1.3M | -$12.8K | -$51.7K | — |
| Financing cash flow | $298.8K | $4.0K | $6.3M | $108.2K | -$28.2K | -$4.9K | -$180.8K | $742.9K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001477932-26-002218.
Others in SIC 8071
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| NTRA | Natera, Inc. | $47.31B | — | 35.9% |
| LH | LABCORP HOLDINGS INC. | $26.51B | 31.3x | 7.2% |
| DGX | QUEST DIAGNOSTICS INC | $26.17B | 27.1x | 11.8% |
| GH | Guardant Health, Inc. | $21.66B | — | 32.9% |
| CAI | Caris Life Sciences, Inc. | $7.08B | — | 97.0% |
| RDNT | RadNet, Inc. | $5.80B | — | 11.5% |
| CELC | Celcuity Inc. | $4.68B | — | — |
| BLLN | BillionToOne, Inc. | $4.61B | 709.9x | 100.0% |